Analyst Price Targets — LGND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 1:20 pm | — | Leerink Partners | $330.00 | $290.10 | TheFly | Ligand initiated with an Outperform at Leerink |
| August 6, 2026 4:01 pm | Joseph Pantginis | H.C. Wainwright | $358.00 | $313.55 | TheFly | Ligand price target raised to $358 from $289 at H.C. Wainwright |
| August 3, 2026 9:51 am | Leland Gershell | Oppenheimer | $326.00 | $287.54 | StreetInsider | Ligand Pharma (LGND) PT Raised to $326 at Oppenheimer |
| July 20, 2026 12:40 pm | Matt Hewitt | Craig-Hallum | $345.00 | $303.03 | TheFly | Ligand price target raised to $345 from $330 at Craig-Hallum |
| July 15, 2026 11:29 am | — | RBC Capital | $340.00 | $300.97 | TheFly | Ligand price target raised to $340 from $262 at RBC Capital |
| July 8, 2026 11:06 am | Annabel Samimy | Stifel Nicolaus | $332.00 | $319.43 | TheFly | Ligand price target raised to $332 from $255 at Stifel |
| April 30, 2026 10:09 am | Joseph Pantginis | H.C. Wainwright | $289.00 | $224.86 | TheFly | Ligand price target raised to $289 from $243 at H.C. Wainwright |
| April 28, 2026 11:36 am | — | RBC Capital | $252.00 | $241.79 | TheFly | Ligand price target raised to $252 from $235 at RBC Capital |
| April 27, 2026 6:05 pm | — | Stifel Nicolaus | $255.00 | $241.79 | TheFly | Ligand price target raised to $255 from $230 at Stifel |
| April 14, 2026 2:43 pm | Joseph Pantginis | H.C. Wainwright | $243.00 | $231.11 | TheFly | Ligand price target raised to $243 from $239 at H.C. Wainwright |
Latest News for LGND
Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity.
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m.
Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,358 shares of the biotechnology company's stock after purchasing an additional 1,900 shares during the quarter.
Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LGND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.